Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Advanced non-small-cell lung cancer (NSCLC) patients without epidermal growth factor receptor
(EGFR) mutations show a poor prognosis. Gemcitabine combined with cisplatin chemotherapy is
an effective treatment measures for EGFR mutation-negative NSCLC patients, but the prognosis
remains poor. Chemotherapy combined with targeted monoclonal antibody treatment may be better
treatment options in these patients. Monoclonal antibodies, such as bevacizumab, can block
tumor growth in different ways. Bevacizumab blocks the ability of tumors to grow new blood
vessels and spread. It is not yet known whether cisplatin and gemcitabine is more effective
when given alone or with bevacizumab. This randomized trial studies how well giving cisplatin
and gemcitabine alone or in combination with Bevacizumab (Avastin) works in treating patients
with stage IIIB/IV non-squamous NSCLC without EGFR mutations.